H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $50.00 price target on Aligos Therapeutics Inc. (NASDAQ: ALGS).

The analyst commented: "On April 16, Aligos Therapeutics announced an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium (pevy) for chronic hepatitis B virus (CHB) infection in Greater China (Mainland China, Taiwan, Hong Kong, and Macau). Under the terms, Aligos will receive a $25 million upfront payment and is eligible for up to $420 million in clinical, regulatory, and sales milestones, along with tiered, high single-digit royalties on net sales. Aligos retains all development and commercialization rights in the United States, Europe, Japan, South Korea, and all other global markets, as well as the right to conduct clinical trials in Greater China — ensuring the deal does not constrain global development programs such as the Phase 2 B-SUPREME trial or future Phase 3 studies. The $25 million upfront extends Aligos' cash runway into 4Q26 based on the current operating plan. On our follow-up call, management noted Aligos continues to evaluate financing strategies, including ongoing partnership discussions around ALG-055009, its THR-β agonist MASH candidate, which could provide additional non-dilutive capital to bridge toward 2027 topline data. We view this transaction as a meaningful source of external validation for pevy from a partner with deep expertise in the Chinese HBV market, and believe the deal positions pevy to capture significant commercial value across the world's largest CHB population while preserving Aligos' ability to maximize value in the U.S. and other major markets. We reiterate our Buy rating and $50 price target on ALGS."

For an analyst ratings summary and ratings history on Aligos Therapeutics Inc. click here. For more ratings news on Aligos Therapeutics Inc. click here.

Shares of Aligos Therapeutics Inc. closed at $7.66 yesterday.

You May Also Be Interested In

• Morgan Stanley Starts Sampo Oyj (SAMPO:FH) (SAXPY) at Equalweight
• JPMorgan Downgrades Progressive Corp. (PGR) to Neutral
• Baird Downgrades CoStar Group (CSGP) to Neutral